SCHEMBL5669604

SCHEMBL5669604

CC(C)C(CS(=O)(=O)N1CCC(c2ccccc2Cl)CC1)C(=O)NO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 3/20 0.41
MMP13 P45452 2/20 0.41
MMP3 P08254 2/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 3/20 0.40
TSHR P16473 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
HCRTR2 O43614 2/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5670613 0.88 ADAM10 (0.46) MMP2MMP13MMP3MAPTHDAC3
SCHEMBL5670609 0.88 ADAM10 (0.46) MMP2MMP13MMP3MAPTHDAC3
SCHEMBL5669934 0.88 CNR1 (0.41) LMNAMAPTALDH1A1NPSR1MMP1
SCHEMBL5669936 0.88 CNR1 (0.41) LMNAMAPTALDH1A1NPSR1MMP1
SCHEMBL5671594 0.87 ADAM10 (0.45) MMP2MMP3TSHRHCRTR2ALDH1A1
SCHEMBL5670514 0.87 ADAM10 (0.45) MMP2MMP3TSHRHCRTR2ALDH1A1
SCHEMBL5670448 0.85 MEN1 (0.47) MMP2MMP13MAPTTSHRHCRTR2
SCHEMBL5669935 0.85 MEN1 (0.47) MMP2MMP13MAPTTSHRHCRTR2
SCHEMBL5670595 0.85 RBP4 (0.50) MMP2MMP13HCRTR2CYP2C19ADAM10
SCHEMBL5670525 0.84 MMP2 (0.47) MMP2MMP13MMP3LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-12-07 US disclosed
EP-1648868-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R&D LTD (GB) 2006-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CD2, CD22, NEU3 MMP2 264/4885MMP13 29/4885MMP3 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.